Prostate cancer
(PCa) represents a common malignancy among elder males and one of the leading
causes of cancer mortality. It may present with a variety of clinical behavior,
including tumors of very low clinical significance but also highly aggressive
tumors with increased risk of relapse after initial treatment.
Nowadays, many
tumors traditionally treated either by radical prostatectomy or by external beam
radiation therapy are considered of low clinical significance and such
patients are placed under active surveillance protocols with purpose to reduce
overtreatment.
As a result, in
the “active surveillance” era, there is a need of establishing strong
prognostic markers identifying aggressive tumors as well as clinical
significant tumors even among these initially characterized of low or
intermediate risk.
No comments:
Post a Comment